Skip to Content
MilliporeSigma
  • urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

The Journal of rheumatology (2013-04-03)
Jason G Lieberthal, David Cuthbertson, Simon Carette, Gary S Hoffman, Nader A Khalidi, Curry L Koening, Carol A Langford, Kathleen Maksimowicz-McKinnon, Philip Seo, Ulrich Specks, Steven R Ytterberg, Peter A Merkel, Paul A Monach
ABSTRACT

Glomerulonephritis (GN) is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but tools for early detection of renal involvement are imperfect. We investigated 4 urinary proteins as markers of active renal AAV: alpha-1 acid glycoprotein (AGP), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL). Patients with active renal AAV (n = 20), active nonrenal AAV (n = 16), and AAV in longterm remission (n = 14) were identified within a longitudinal cohort. Urinary biomarker concentrations (by ELISA) were normalized for urine creatinine. Marker levels during active AAV were compared to baseline remission levels (from 1-4 visits) for each patient. Areas under receiver-operating characteristic curves (AUC), sensitivities, specificities, and likelihood ratios (LR) comparing disease states were calculated. Baseline biomarker levels varied among patients. All 4 markers increased during renal flares (p < 0.05). MCP-1 discriminated best between active renal disease and remission: a 1.3-fold increase in MCP-1 had 94% sensitivity and 89% specificity for active renal disease (AUC = 0.93, positive LR 8.5, negative LR 0.07). Increased MCP-1 also characterized 50% of apparently nonrenal flares. Change in AGP, KIM-1, or NGAL showed more modest ability to distinguish active renal disease from remission (AUC 0.71-0.75). Hematuria was noted in 83% of active renal episodes, but also 43% of nonrenal flares and 25% of remission samples. Either urinary MCP-1 is not specific for GN in AAV, or it identifies early GN not detected by standard assessment and thus has potential to improve care. A followup study with kidney biopsy as the gold standard is needed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Total Protein Kit, Micro